Quinten Health, Aetion partner on AI for research studies

By The Science Advisory Board staff writers

September 23, 2021 -- Artificial intelligence (AI) developer Quinten Health and Aetion, a real-world evidence technology provider, have formed a strategic partnership to offer an integrated range of products and services.

The partnership will leverage Quinten Health's analytics and AI products and Aetion's evidence platform, which analyzes real-world data to produce transparent and scientifically validated evidence on the safety, efficacy, and value of medical treatments and technologies, the companies said.

The partnership allows clinicians, biopharma, and regulatory and health technology assessment agencies to use Quinten Health's AI and machine-learning algorithms to generate a range of scientific hypotheses and then validate those hypotheses using Aetion's evidence platform.

AI drug development startups raised $2.1B in 1st half of 2021
The market for artificial intelligence (AI) in drug development and discovery has been red-hot in recent years. The potential impact that AI can offer...
From lab to clinic: How AI can help
Clinical trials are an important checkpoint in moving therapies from the lab to the clinic, and artificial intelligence (AI) software can help researchers...

Copyright © 2021 scienceboard.net

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter